Patents by Inventor Ian J. Mohr
Ian J. Mohr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220031779Abstract: The present invention relates to variants of herpes simplex virus (HSV) that selectively infect and replicate in cancer cells, including HSV strains that selectively infect and replicate in bladder cancer cells. Preferred HSV of the invention have intact endogenous Us11 and Us12 genes and have genes encoding ICP34.5 replaced with a gene encoding Us11 fused to an HSV immediate early (IE) promoter. The variant HSV of the invention also comprise one or more additional heterologous genes encoding immunomodulatory polypeptides. Methods and compositions using these variant HSV, for example, for treating cancer in a subject, are also provided.Type: ApplicationFiled: October 15, 2021Publication date: February 3, 2022Inventors: Ian J. Mohr, Matthew Mulvey
-
Patent number: 11147846Abstract: The present invention relates to variants of herpes simplex virus (HSV) that selectively infect and replicate in cancer cells, including HSV strains that selectively infect and replicate in bladder cancer cells. Preferred HSV of the invention have intact endogenous Us11 and Us12 genes and have genes encoding ICP34.5 replaced with a gene encoding Us11 fused to an HSV immediate early (IE) promoter. The variant HSV of the invention also comprise one or more additional heterologous genes encoding immunomodulatory polypeptides. Methods and compositions using these variant HSV, for example, for treating cancer in a subject, are also provided.Type: GrantFiled: September 20, 2019Date of Patent: October 19, 2021Assignees: New York University, BeneVir Biopharm, Inc.Inventors: Ian J. Mohr, Matthew Mulvey
-
Patent number: 10967015Abstract: A method for treating a tumor by administering to a subject in need of such treatment an effective amount for treating the tumor of a Poxviridae decapping deficient mutant virus. Also disclosed are mutant Poxviridae and pharmaceutical formulations for use in the method.Type: GrantFiled: June 15, 2016Date of Patent: April 6, 2021Assignee: New York UniversityInventor: Ian J Mohr
-
Publication number: 20200113956Abstract: The present invention relates to variants of herpes simplex virus (HSV) that selectively infect and replicate in cancer cells, including HSV strains that selectively infect and replicate in bladder cancer cells. Preferred HSV of the invention have intact endogenous Us11 and Us12 genes and have genes encoding ICP34.5 replaced with a gene encoding Us11 fused to an HSV immediate early (IE) promoter. The variant HSV of the invention also comprise one or more additional heterologous genes encoding immunomodulatory polypeptides. Methods and compositions using these variant HSV, for example, for treating cancer in a subject, are also provided.Type: ApplicationFiled: September 20, 2019Publication date: April 16, 2020Inventors: Ian J. Mohr, Matthew Mulvey
-
Patent number: 10456432Abstract: The present invention relates to variants of herpes simplex virus (HSV) that selectively infect and replicate in cancer cells, including HSV strains that selectively infect and replicate in bladder cancer cells. Preferred HSV of the invention have intact endogenous Us11 and Us12 genes and have genes encoding ICP34.5 replaced with a gene encoding Us11 fused to an HSV immediate early (IE) promoter. The variant HSV of the invention also comprise one or more additional heterologous genes encoding immunomodulatory polypeptides. Methods and compositions using these variant HSV, for example, for treating cancer in a subject, are also provided.Type: GrantFiled: September 10, 2018Date of Patent: October 29, 2019Assignees: New York University, BeneVir Biopharm, Inc.Inventors: Ian J. Mohr, Matthew C. Mulvey
-
Publication number: 20180369301Abstract: The present invention relates to variants of herpes simplex virus (HSV) that selectively infect and replicate in cancer cells, including HSV strains that selectively infect and replicate in bladder cancer cells. Preferred HSV of the invention have intact endogenous Us11 and Us12 genes and have genes encoding ICP34.5 replaced with a gene encoding Us11 fused to an HSV immediate early (IE) promoter. The variant HSV of the invention also comprise one or more additional heterologous genes encoding immunomodulatory polypeptides. Methods and compositions using these variant HSV, e.g. for example, for treating cancer in a subject, are also provided.Type: ApplicationFiled: September 10, 2018Publication date: December 27, 2018Inventors: Ian J. Mohr, Matthew C. Mulvey
-
Publication number: 20180318366Abstract: A method for treating a tumor by administering to a subject in need of such treatment an effective amount for treating the tumor of a Poxviridae decapping deficient mutant virus. Also disclosed are mutant Poxviridae and pharmaceutical formulations for use in the method.Type: ApplicationFiled: June 15, 2016Publication date: November 8, 2018Inventor: Ian J Mohr
-
Patent number: 10105404Abstract: The present invention relates to variants of herpes simplex virus (HSV) that selectively infect and replicate in cancer cells, including HSV strains that selectively infect and replicate in bladder cancer cells. Preferred HSV of the invention have intact endogenous Us11 and Us12 genes and have genes encoding ICP34.5 replaced with a gene encoding Us11 fused to an HSV immediate early (IE) promoter. The variant HSV of the invention also comprise one or more additional heterologous genes encoding immunomodulatory polypeptides. Methods and compositions using these variant HSV, for example, for treating cancer in a subject, are also provided.Type: GrantFiled: April 17, 2017Date of Patent: October 23, 2018Assignees: New York University, Benevir Biopharm, Inc.Inventors: Ian J. Mohr, Matthew C. Mulvey
-
Publication number: 20170216381Abstract: The present invention relates to variants of herpes simplex virus (HSV) that selectively infect and replicate in cancer cells, including HSV strains that selectively infect and replicate in bladder cancer cells. Preferred HSV of the invention have intact endogenous Us11 and Us12 genes and have genes encoding ICP34.5 replaced with a gene encoding Us11 fused to an HSV immediate early (IE) promoter. The variant HSV of the invention also comprise one or more additional heterologous genes encoding immunomodulatory polypeptides. Methods and compositions using these variant HSV, e.g., for treating cancer in a subject, are also provided.Type: ApplicationFiled: April 17, 2017Publication date: August 3, 2017Inventors: Ian J. Mohr, Matthew C. Mulvey
-
Patent number: 9623059Abstract: The present invention relates to variants of herpes simplex virus (HSV) that selectively infect and replicate in cancer cells, including HSV strains that selectively infect and replicate in bladder cancer cells. Preferred HSV of the invention have intact endogenous Us11 and Us12 genes and have genes encoding ICP34.5 replaced with a gene encoding Us11 fused to an HSV immediate early (IE) promoter. The variant HSV of the invention also comprise one or more additional heterologous genes encoding immunomodulatory polypeptides. Methods and compositions using these variant HSV, for example, for treating cancer in a subject, are also provided.Type: GrantFiled: September 7, 2012Date of Patent: April 18, 2017Assignees: New York University, Benevir Biopharm, Inc.Inventors: Ian J. Mohr, Matthew C. Mulvey
-
Publication number: 20150110822Abstract: The present invention relates to variants of herpes simplex virus (HSV) that selectively infect and replicate in cancer cells, including HSV strains that selectively infect and replicate in bladder cancer cells. Preferred HSV of the invention have intact endogenous Us11 and Us12 genes and have genes encoding ICP34.5 replaced with a gene encoding Us11 fused to an HSV immediate early (IE) promoter. The variant HSV of the invention also comprise one or more additional heterologous genes encoding immunomodulatory polypeptides. Methods and compositions using these variant HSV, e.g., for treating cancer in a subject, are also provided.Type: ApplicationFiled: September 7, 2012Publication date: April 23, 2015Applicants: BENEVIR BIOPHARM, INC., NEW YORK UNIVERSITYInventors: Ian J. Mohr, Matthew C. Mulvey
-
Patent number: 5925516Abstract: Medicaments, and methods of identifying the same, are described that are useful for treating papillomavirus diseases that have the characteristics of preventing, interfering with, or reversing the binding of the appropriate papillomavirus proteins E1 or E2 to a nucleotide sequence homologous to a nucleotide sequence present in the papillomavirus genome, or of the formation of a complex consisting of papillomavirus proteins E1 and E2, or the binding of the complex to the nucleotide sequence.Type: GrantFiled: April 27, 1995Date of Patent: July 20, 1999Assignees: Chiron Corporation, University of CaliforniaInventors: Michael R. Botchan, Robin Clark, Ian J. Mohr, Shaw Sun
-
Patent number: 5824318Abstract: Isolated tumoricidal herpetic viruses, in particular neurotrophic herpes viruses, T-lymphotrophic viruses, and B-lymphotrophic viruses, which are avirulent and capable of selectively replicating in and destroying neoplastic cells, and pharmaceutical compositions, vaccines, and methods of destroying neoplastic cells employing the isolated tumoricidal herpetic viruses are described. A method of isolating tumoricidal herpetic viruses by sequentially passaging attenuated, avirulent herpetic viruses on neoplastic cells which fail to support replication of the herpetic viruses and isolating the viruses which grow on the neoplastic cells is also described. Herpes simplex virus mutants having a genome from which the .gamma.34.5 genes have been deleted and which require at least one additional mutation to produce a non-neurovirulent herpes simplex virus which selectively replicates in and destroys neoplastic cells are also described.Type: GrantFiled: July 24, 1996Date of Patent: October 20, 1998Assignee: American Cyanamid CompanyInventors: Ian J. Mohr, Yakov Gluzman, deceased
-
Patent number: 5620849Abstract: Compositions and methods for identifying inhibitors of papilloma virus replication are described consisting of soluble cellular extracts supplemented with purified viral E1 and E2 proteins.Type: GrantFiled: September 23, 1994Date of Patent: April 15, 1997Assignees: Cetus Corporation, The Regents of the University of CaliforniaInventors: Michael R. Botchan, Liu Yang, Rong Li, Ian J. Mohr, Robin Clark
-
Patent number: 5464936Abstract: Medicaments, and methods of identifying the same, are described that are useful for treating papillomavirus diseases that have the characteristics of preventing, interfering with, or reversing the binding of the appropriate papillomavirus proteins E1 or E2 to a nucleotide sequence homologous to a nucleotide sequence present in the papillomavirus genome, or of the formation of a complex consisting of papillomavirus proteins E1 and E2, or the binding of the complex to the nucleotide sequence.Type: GrantFiled: December 21, 1990Date of Patent: November 7, 1995Assignees: Cetus Oncology Corporation, University of CaliforniaInventors: Michael R. Botchan, Robin Clark, Ian J. Mohr, Shaw Sun